pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,438 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT979Endpoints752BioPharma Dive287BioSpace188Fierce Biotech182onclive165globenewswire health73raps
therapy area
allOncology5737Rare Disease1267Cardiology1065Immunology966Hematology952Pulmonology848Vaccines
  • HCA Healthcare cuts 2026 profit outlook as uninsured patient numbers rise after ACA subsidy expiration
    HCA Healthcare, the largest U.S. hospital chain, announced on Tuesday that it is lowering its profit outlook for 2026. The revision reflects a higher-than-expected number of uninsured patients in…
    STAT · 1mo agoNegative↗ source
  • Avere Therapeutics to go public via reverse merger, secures $320M to advance long-acting psoriasis pill
    Avere Therapeutics, a privately held immunology drug developer, announced a plan to become a public company through a reverse merger with NextCure. The transaction includes $320 million in new cap…
    BioPharma Dive · 1mo agoDealPositive↗ source
← prev
page 38 of 98
next →
66
fda recalls43
fda medwatch32
fda press25
826
Psychiatry & CNS698
Ophthalmology394
Pain347
Endocrinology & Metabolism343
Infectious Disease336
  • Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapies
    Biogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the m…
    STAT · 1mo agoPositive readoutPositive↗ source
  • Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trial
    Biogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 million
    AstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy. The agreement gives AstraZeneca full…
    Endpoints · 1mo agoDealNeutral↗ source
  • Celcuity receives FDA approval for Revtorpyk breast cancer therapy
    Celcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…
    Endpoints · 1mo agoApprovalPositive↗ source
  • Bipartisan Bill to Limit US Biotech Deals with China Remains in Limbo
    A bipartisan bill introduced in the House seeks to bar U.S. biotechnology firms from entering into collaborations or licensing agreements with Chinese companies. The proposal sparked strong reacti…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Live webcast examines why biotech IPOs are gaining momentum again
    Drew Armstrong, executive editor at Endpoints News, announced a live webcast scheduled for July 15 at 12 p.m. ET. The session will feature Parabilis CEO Mathai Mammen and Kailera CEO Ron Renaut, al…
    Endpoints · 1mo agoPositive↗ source
  • Erasca seeks $550M in public offering to fund KRAS drug development
    Erasca announced a public offering targeting $550 million to advance its KRAS-targeted drug program. The biotech said the capital will support ongoing research and potential clinical trials for its…
    Endpoints · 1mo agoDealNeutral↗ source
  • AI drug-discovery startup Chai Discovery raises $400 million in Series C, tripling its valuation
    Chai Discovery, a startup focused on using artificial intelligence for drug discovery, announced a new Series C financing round that brought in $400 million. The capital injection was led by existi…
    Endpoints · 1mo agoDealPositive↗ source
  • Draig Therapeutics secures $65M Series B to advance brain-drug trials
    Draig Therapeutics announced a $65 million Series B financing led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace and other investors. The capital will fund…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Biogen's tau therapy shows mixed Alzheimer's results, low dose outperforms higher dose
    At the Alzheimer's Association International Conference in London, Biogen presented data on its experimental tau‑targeting therapy for Alzheimer's disease. The trial showed that the drug produced…
    Endpoints · 1mo agoNegative readoutNeutral↗ source
  • Innovent Biologics partners with Spero to advance autoimmune drug candidate beyond GSK antibiotic
    Innovent Biologics has announced a new partnership with Spero, a smaller biopharma firm, to develop an autoimmune drug candidate originating from Suzhou, China. The collaboration follows a series…
    Endpoints · 1mo agoDealPositive↗ source
  • Former FDA toxicologist says agency approved Zyn nicotine pouches without fully knowing their composition
    Former FDA toxicologist Christy Leppanen alleges the agency authorized Zyn nicotine pouches without complete safety data on the pouch material. Leppanen, who led a microplastics exposure project a…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Deepfake videos of doctors threaten trust in telehealth and digital care
    A patient recently presented a video that appeared to show her physician in a white coat, recommending an over‑the‑counter hormone supplement and disparaging standard treatments. The doctor confirm…
    STAT · 1mo agoNegative↗ source
  • Alcohol Use Remains Leading Cause of Death in U.S., New Data Highlights Hidden Epidemic
    STAT's latest series reveals that alcohol kills more Americans each year than all illicit drugs combined, yet it remains largely overlooked by health officials and the public. Ten charts illustrat…
    STAT · 1mo agoNegative↗ source
  • AI competition shows better data beats larger models in drug metabolism predictions
    Inductive Bio emerged as the winner of a recent drug metabolism AI competition, but the final standings revealed a 28-way statistical tie, underscoring that the quality of data can outweigh model s…
    STAT · 1mo agoPositive readoutPositive↗ source
  • Cayman court orders Apple Tree Partners’ general partner to give up control of venture fund
    A Cayman Islands court ruled that Seth Harrison, the general partner of biotech venture firm Apple Tree Partners, must relinquish oversight of the fund. The order could shift management to two cour…
    BioPharma Dive · 1mo agoRegulatoryNegative↗ source
  • Anthropic launches Claude Science AI platform for biotech labs in Kendall Square
    Anthropic has introduced Claude Science, an application that tailors its large language model for use in biopharma research laboratories. The tool is being positioned for the Kendall Square biotech…
    STAT · 1mo agoNeutral↗ source
  • California settles with bankrupt Carbon Health, signaling crackdown on digital health workarounds
    At the end of June, California's attorney general reached a settlement with Carbon Health, a clinic operator that has filed for bankruptcy. The settlement follows accusations from the state Justic…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Former Akero executives team up with Fairmount to launch new immunology company
    The former executive team of Akero Therapeutics, which was recently acquired by Novo Nordisk, has announced the formation of a new immunology-focused company. They are partnering with investment fi…
    STAT · 1mo agoNeutral↗ source
  • US appeals court revives Teva lawsuit alleging Lilly breached generic Forteo agreement
    A U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly. The case alleges that Lilly broke an agreement that permitted Teva to sell a generic version of Lilly's o…
    STAT · 1mo agoNegative↗ source
  • Draig Therapeutics raises $65 million Series B to push depression drug targeting synapse repair
    Draig Therapeutics announced it has closed a $65 million Series B financing round that was oversubscribed. The capital will be used to advance its neuropsychiatry pipeline, with the lead program f…
    Endpoints · 1mo agoDealPositive↗ source
  • Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and Biogen
    Lyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
    Endpoints · 1mo agoPositive↗ source
  • Former Akero executives launch Avere Therapeutics, unveiling China-sourced pipeline drug and reverse merger plan
    The former leadership team of Akero Therapeutics announced the creation of a new in‑licensing company called Avere Therapeutics. The launch was made public on Tuesday and includes a pipeline drug…
    Endpoints · 1mo agoDealNeutral↗ source